Brief Summary
The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronica long-lasting disease that changes slowly over time lymphocytic leukemia (CLL) or small lymphocytic lymphomacancers of the lymphatic system (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).
Intervention / Treatment
- Drug: BGB-16673
- Drug: Pirtobrutinib
Inclusion Criteria
- Confirmed diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of CLL or SLL, requiring treatment, based on 2018 iwCLL criteria
- Previously received treatment for CLL/SLL with a covalent Bruton tyrosine kinase inhibitor (cBTKi). Patients should have disease relapsed after or refractory to at least 1 line of therapy including a cBTKi.
- Participants with SLL must have measurable disease by computed tomography/magnetic resonance imagingtests that create detailed images of areas inside the body, defined as ≥ 1 lymph nodea small lump or mass of tissue in your body > 1.5 cm in longest diameter and measurable in 2 perpendicular diameters.